measuring response with immuno-oncology agents in nsclc
Published 8 years ago • 93 plays • Length 3:36Download video MP4
Download video MP3
Similar videos
-
1:18
diagnostic testing to identify pd-l1 inhibitor response in lung cancer
-
3:44
biomarkers for selection of immuno-oncology agents in nsclc
-
46:35
the role of immunotherapy in non small cell lung cancer nsclc
-
3:20
immuno-oncology in nsclc: cost versus benefit
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
5:10
immuno-oncology combination therapy in nsclc
-
26:57
segment 2: molecular targets in nsclc
-
1:13:19
state-of-the-art in combination immuno/radiotherapy for non-small cell lung cancer
-
7:16
immuno-oncology combination therapy: which patients with nsclc?
-
10:35
measuring response to immunotherapy in melanoma
-
4:52
targeting the immune system in non-small cell lung cancer
-
56:08
gaining confidence in predicting and assessing response to cancer immunotherapies
-
22:06
basics of immunotherapy in nsclc
-
55:38
novel therapy for lung cancer: from targeted therapy to immuno-therapy and back again!
-
6:42
pseudoprogression with checkpoint inhibitors in non-small cell lung cancer
-
22:06
the basics of immunotherapy in non-small cell lung cancer (nsclc)
-
1:01:11
immuno-oncology: a deep dive into non-small cell lung cancer
-
45:17
iclio webinar: reflex testing guidelines for immunotherapy in non small cell lung cancer
-
57:44
lung cancer? what patients need to know about immunotherapy, with leena gandhi